A megakaryocyte with no platelets: Anti-platelet antibodies, apoptosis, and platelet production

References

• Rodeghiero F, Besalduch J, Michel M, Provan D, Grotzinger K, Thompson G. Treatment practices in adults with chronic immune thrombocytopenia – A European perspective. Eur J Haematol 2010; 84(2)160–168
   PubMed Web of Science ®Google Scholar
• George JN, Aster RH. Drug-induced thrombocytopenia: Pathogenesis, evaluation, and management. Hematology, American Society of Hematology, Education Program 2009; 153–158.
   Google Scholar
• Christie DJ, Aster RH. Drug-antibody-platelet interaction in quinine- and quinidine-induced thrombocytopenia. J Clin Invest 1982; 70(5)989–998
   PubMed Web of Science ®Google Scholar
• Chong BH. Drug-induced immune thrombocytopenia. Platelets 1991; 2(4)173–181
   PubMedGoogle Scholar
• Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. New Engl J Med 2007; 357(6)580–587
   PubMed Web of Science ®Google Scholar
• Newland AC, Macey MG. Immune thrombocytopenia and Fc receptor-mediated phagocyte function. Ann Hematol 1994; 69(2)61–67
   PubMedGoogle Scholar
• Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LMS, Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9(9)1123–1124
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, Van Der Want JJL, Esselink MT, Koornstra JJ, Smit JW, Louwes H, Vellenga E, De Wolf JTM. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103(2)500–506
   PubMed Web of Science ®Google Scholar
• Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008; 99(1)4–13
   PubMed Web of Science ®Google Scholar
• Stockelberg D, Hou M, Jacobsson S, Kutti J, Wadenvik H. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol 1996; 56(1–2)72–77
   PubMedGoogle Scholar
• McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000; 37(3)239–248
   PubMed Web of Science ®Google Scholar
• Asvadi P, Ahmadi Z, Chong BH. Drug-induced thrombocytopenia: Localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood 2003; 102(5)1670–1677
   PubMed Web of Science ®Google Scholar
• Visentin GP, Newman PJ, Aster RH. Characteristics of quinine- and quinidine-induced antibodies specific for platelet glycoproteins IIb and IIIa. Blood 1991; 77(12)2668–2676
   PubMed Web of Science ®Google Scholar
• Peterson JA, Nelson TN, Kanack AJ, Aster RH. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 2008; 111(3)1234–1239
   PubMed Web of Science ®Google Scholar
• Burgess JK, Lopez JA, Berndt MC, Dawes I, Chesterman CN, Chong BH. Quinine-dependent antibodies bind a restricted set of epitopes on the glycoprotein Ib-IX complex: Characterization of the epitopes. Blood 1998; 92(7)2366–2373
   PubMed Web of Science ®Google Scholar
• Gao C, Boylan B, Bougie D, Gill JC, Birenbaum J, Newman DK, Aster RH, Newman PJ. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest 2009; 119(3)504–511
   PubMed Web of Science ®Google Scholar
• McKenzie SE, Taylor SM, Malladi P, Yuhan H, Cassel DL, Chien P, Schwartz E, Schreiber AD, Surrey S, Reilly MP. The role of the human Fc receptor FcŒ ≥ RIIA in the immune clearance of platelets: A transgenic mouse model. J Immunol 1999; 162(7)4311–4318
   PubMed Web of Science ®Google Scholar
• Tomer A. Human marrow megakaryocyte differentiation: Multiparameter correlative analysis identifies von Willebrand factor as a sensitive and distinctive marker for early (2N and 4N) megakaryocytes. Blood 2004; 104(9)2722–2727
   PubMedGoogle Scholar
• Vazquez JJ, Lewis JH. Immunocytochemical studies on platelets. The demonstration of a common antigen in human platelets and megakaryocytes. Blood 1960; 16: 968–974
   PubMedGoogle Scholar
• De Laval M. Mise en evidence d'antigenes plaquettaires dans le cytoplasme des megacaryocytes par la technique des anticorps fluorescents. CR SOC Biol (Paris) 1967; 161: 948–951
   PubMedGoogle Scholar
• Stahl CP, Zucker-Franklin D, McDonald TP. Incomplete antigenic cross-reactivity between platelets and megakaryocytes: Relevance to ITP. Blood 1986; 67(2)421–428
   PubMed Web of Science ®Google Scholar
• Vinci G, Tabilio A, Deschamps JF. Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol 1984; 56(4)589–605
   PubMedGoogle Scholar
• Mazur EM, Hoffman R, Chasis J. Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 1981; 57(2)277–286
   PubMedGoogle Scholar
• McMillan R, Luiken GA, Levy R. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978; 239(23)2460–2462
   PubMed Web of Science ®Google Scholar
• Perdomo J, Yan F, Ahmadi Z, Jiang XM, Stocker R, Chong BH. Quinine-induced thrombocytopenia: Drug-dependent GPIb/IX antibodies inhibit megakaryocyte and proplatelet production in vitro. Blood 2011; 117(22)5975–5986
   PubMed Web of Science ®Google Scholar
• Hoffman R, Zaknoen S, Yang HH. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. New Engl J Med 1985; 312(18)1170–1174
   PubMedGoogle Scholar
• Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, Nugent DJ. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102(3)887–895
   PubMed Web of Science ®Google Scholar
• McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103(4)1364–1369
   PubMed Web of Science ®Google Scholar
• Balduini A, Pallotta I, Malara A, Lova P, Pecci A, Viarengo G, Balduini CL, Torti M. Adhesive receptors, extracellular proteins and myosin IIA orchestrate proplatelet formation by human megakaryocytes. J Thromb Haemost 2008; 6(11)1900–1907
   PubMed Web of Science ®Google Scholar
• Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999; 93(6)1951–1958
   PubMed Web of Science ®Google Scholar
• Greinacher A, Fuerll B, Zinke H, Mullejans B, Kruger W, Michetti N, Motz W, Schwertz H. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood 2009; 114(6)1250–1253
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Determinants of platelet number and regula- tion of thrombopoiesis. Hematology, American Society of Hematology, Education Program 2009;147–152.
   Google Scholar
• Li J, Kuter DJ. The end is just the beginning: Megakaryocyte apoptosis and platelet release. Int J Hematol 2001; 74(4)365–374
   PubMedGoogle Scholar
• White MJ, Kile BT. Apoptotic processes in megakaryocytes and platelets. Semin Hematol 2010; 47(3)227–234
   PubMed Web of Science ®Google Scholar
• De Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, Hermine O, Kroemer G, Vainchenker W, Debili N. Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002; 100(4)1310–1317
   PubMed Web of Science ®Google Scholar
• Clarke MCH, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized megakaryocyte death generates functional platelets committed to caspase-independent death. J Cell Biol 2003; 160(4)577–587
   PubMed Web of Science ®Google Scholar
• Yang L, Wang L, Zhao CH, Zhu XJ, Hou Y, Peng J, Hou M. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010; 116(20)4307–4316
   PubMedGoogle Scholar
• Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, Adams JM. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 1999; 96(26)14943–14948
   PubMedGoogle Scholar
• Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F, Adams JM, Strasser A. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286(5445)1735–1738
   PubMedGoogle Scholar
• Kozuma Y, Yuki S, Ninomiya H, Nagasawa T, Kojima H. Caspase activation is involved in early megakaryocyte differentiation but not in platelet production from megakaryocytes. Leukemia 2009; 23(6)1080–1086
   PubMedGoogle Scholar
• Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011; 208(10)2017–2031
   PubMed Web of Science ®Google Scholar
• Morison IM, Cramer Borde EM, Cheesman EJ, Cheong PL, Holyoake AJ, Fichelson S, Weeks RJ, Lo A, Davies SMK, Wilbanks SM, et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008; 40(4)387–389
   PubMed Web of Science ®Google Scholar
• Wagner KU, Claudio E, Rucker EB, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U, Hennighausen L. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 2000; 127(22)4949–4958
   PubMed Web of Science ®Google Scholar
• Kaluzhny Y, Yu G, Sun S, Toselli PA, Nieswandt B, Jackson CW, Ravid K. BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood 2002; 100(5)1670–1678
   PubMed Web of Science ®Google Scholar
• Zauli G, Catani L, Gibellini D, Carla Re M, Vianelli N, Colangeli V, Celeghini C, Capitani S, La Placa M. Impaired survival of bone marrow GPIIb/IIIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol 1996; 92(3)711–717
   PubMed Web of Science ®Google Scholar
• Pisciotta AV, Stefanini M, Dameshek W. Studies on platelets. X. Morphologic characteristics of megakaryocytes by phase contrast microscopy in normals and in patients with idiopathic thrombocytopenic purpura. Blood 1953; 8(8)703–723
   PubMedGoogle Scholar
• Wentworth AD, Jones LH, Wentworth P, Jr, Janda KD, Lerner RA. Antibodies have the intrinsic capacity to destroy antigens. Proc Natl Acad Sci USA 2000; 97(20)10930–10935
   PubMedGoogle Scholar
• Dumont A, Hehner SP, Hofmann TG, Ueffing M, Dröge W, Schmitz ML. Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-kB. Oncogene 1999; 18(3)747–757
   PubMedGoogle Scholar
• Lopez JJ, Salido GM, Gómez-Arteta E, Rosado JA, Pariente JA. Thrombin induces apoptotic events through the generation of reactive oxygen species in human platelets. J Thromb Haemost 2007; 5(6)1283–1291
   PubMedGoogle Scholar
• Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV–1-related immune thrombocytopenia. Cell 2001; 106(5)551–561
   PubMed Web of Science ®Google Scholar
• Arthur JF, Shen Y, Gardiner EE, Coleman L, Kenny D, Andrews RK, Berndt MC. TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets. J Thromb Haemost 2011; 9(1)163–172
   PubMedGoogle Scholar
• Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008; 111(3)1594–1602
   PubMedGoogle Scholar
• Du X, Fox JE, Pei S. Identification of a binding sequence for the 14-3-3 protein within the cytoplasmic domain of the adhesion receptor, platelet glycoprotein Iba. J Biol Chem 1996; 271(13)7362–7367
   PubMedGoogle Scholar
• Mu FT, Andrews RK, Arthur JF, Munday AD, Cranmer SL, Jackson SP, Stomski FC, Lopez AF, Berndt MC. A functional 14-3-3{zeta}-independent association of PI3-kinase with glycoprotein Ib{alpha}, the major ligand-binding subunit of the platelet glycoprotein Ib-IX-V complex. Blood 2008; 111(9)4580–4587
   PubMedGoogle Scholar
• Subramanian RR, Masters SC, Zhang H, Fu H. Functional conservation of 14-3-3 isoforms in inhibiting Bad-induced apoptosis. Exp Cell Res 2001; 271(1)142–151
   PubMed Web of Science ®Google Scholar
• Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H, Tsujimoto Y. 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 2003; 278(3)2058–2065
   PubMedGoogle Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4(12)988–1004
   PubMed Web of Science ®Google Scholar
• Li S, Wang Z, Liao Y, Zhang W, Shi Q, Yan R, Ruan C, Dai K. The glycoprotein Ibalpha–von Willebrand factor interaction induces platelet apoptosis. J Thromb Haemost 2010; 8(2)341–350
   PubMed Web of Science ®Google Scholar
• Van Der Wal DE, Du VX, Lo KSL, Rasmussen JT, Verhoef S, Akkerman JWN. Platelet apoptosis by cold-induced glycoprotein Ib{alpha} clustering. J Thromb Haemost 2010; 8(11)2554–2562
   PubMed Web of Science ®Google Scholar
• Piguet PF, Vesin C. Modulation of platelet caspases and life-span by anti-platelet antibodies in mice. Eur J Haematol 2002; 68(5)253–261
   PubMedGoogle Scholar
• Cunningham JG, Meyer SC, Fox JEB. The cytoplasmic domain of the GPIba-subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology. J Biol Chem 1996; 271(19)11581–11587
   PubMedGoogle Scholar
• Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: Ultrastructural study using a transgenic model. Exp Hematol 2002; 30(4)352–360
   PubMedGoogle Scholar
• Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D. Influence of auto-antibody specificities on the clinical course in patients with chronic and acute ITP. Platelets 2000; 11(2)94–98
   PubMed Web of Science ®Google Scholar
• Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007; 92(2)283–284
   PubMed Web of Science ®Google Scholar
• Webster ML, Sayeh E, Crow M, Chen P, Nieswandt B, Freedman J, Ni H. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006; 108(3)943–946
   PubMedGoogle Scholar
• Liang SX, Pinkevych M, Khachigian LM, Parish CR, Davenport MP, Chong BH. Drug-induced thrombocytopenia: Development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG. Blood 2010; 116(11)1958–1960
   PubMedGoogle Scholar
• Choi CW, Kim BS, Seo JH, Shin SW, Kim YH, Kim JS, Sohn SK, Shin DG, Ryoo HM, Lee KH, et al. Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. Am J Hematol 2001; 66(3)197–202
   PubMedGoogle Scholar
• Holt D, Brown J, Terrill K, Goldsby R, Meyers RL, Heximer J, Nordfors B, Slayton WB. Response to intravenous immunoglobulin predicts splenectomy response in children with immune thrombocytopenic purpura. Pediatrics 2003; 111(1)87–90
   PubMedGoogle Scholar
• Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100(6)2087–2093
   PubMed Web of Science ®Google Scholar
• Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO, Ruisi MM, Gernsheimer TB, Beer JH, et al. Platelet production and platelet destruction: Assessing mechanisms of treatment effect in immune thrombocytopenia (ITP). Blood 2011;117(21):5723–5732
   Google Scholar
• Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010; 47(3)243–248
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115(2)168–186
   PubMed Web of Science ®Google Scholar
• Gardiner EE, Thom JY, Al-Tamimi M, Hughes A, Berndt MC, Andrews RK, Baker RI. Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. Br J Haematol 2010; 149(4)625–628
   PubMedGoogle Scholar
• Alimardani G, Guichard J, Fichelson S, Cramer EM. Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets. Thromb Haemost 2002; 88(6)1039–1046
   PubMedGoogle Scholar
• Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 2003; 11(1)11–23
   PubMed Web of Science ®Google Scholar